Glycovax Pharma

Press releases

Glycovax Pharma launches a highly performant SLA Adjuvant

MONTREAL, Canada July 8, 2025 – Glycovax Pharma Inc. is taking an important step forward in its contribution to the vaccine industry with the large-scale production of sulfated lactosyl archaeol (SLA) archaeosomes, a new glycolipidic vaccine adjuvant developed by the National Research Council of Canada (NRC). This NRC license represents a major strategic development for…

Glycovax Pharma commercializes a more affordable CRM197 protein

Montreal, Canada, June 9, 2025 – Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM197 protein for use in numerous conjugate vaccines for human and animal vaccines. The National Research Council of Canada (NRC) has developed a unique and highly efficient production system for CRM197. Glycovax has refined its production to meet regulatory requirements…